Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALT

ALT - Altimmune Inc Stock Price, Fair Value and News

8.87USD+0.65 (+7.91%)Market Closed
Watchlist

Market Summary

USD8.87+0.65
Market Closed
7.91%

ALT Alerts

  • JANUS HENDERSON GROUP PLC reported owning 0% of ALT [2024-02-12]

ALT Stock Price

View Fullscreen

ALT RSI Chart

ALT Valuation

Market Cap

476.6M

Price/Earnings (Trailing)

-6.07

Price/Sales (Trailing)

106.73

EV/EBITDA

-4.43

Price/Free Cashflow

-6.22

ALT Price/Sales (Trailing)

ALT Profitability

EBT Margin

-1925.40%

Return on Equity

-52.17%

Return on Assets

-47.11%

Free Cashflow Yield

-16.09%

ALT Fundamentals

ALT Revenue

Revenue (TTM)

4.4M

Rev. Growth (Yr)

18.0K%

Rev. Growth (Qtr)

5.9K%

ALT Earnings

Earnings (TTM)

-78.5M

Earnings Growth (Yr)

12.1%

Earnings Growth (Qtr)

-28.7%

Breaking Down ALT Revenue

Last 7 days

-16.1%

Last 30 days

-27%

Last 90 days

259.0%

Trailing 12 Months

-34.8%

How does ALT drawdown profile look like?

ALT Financial Health

Current Ratio

12.89

Debt/Equity

0

Debt/Cashflow

-129.76

ALT Investor Care

Shares Dilution (1Y)

9.30%

Diluted EPS (TTM)

-1.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
20216.8M6.2M3.4M4.4M
20205.1M4.2M6.4M8.2M
201910.6M9.8M7.8M5.8M
201813.1M12.5M10.6M10.3M
20173.1M5.4M9.0M10.7M
20164.6M4.2M3.9M3.8M
201513.5M11.0M11.2M10.6M
201415.2M14.5M12.0M10.2M
201325.5M23.5M20.3M17.9M
201224.1M24.0M25.4M25.2M
201121.8M22.6M23.4M24.3M
201000021.0M

Tracking the Latest Insider Buys and Sells of Altimmune Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 02, 2024
roberts m scot
acquired
-
-
7,775
chief scientific officer
Feb 02, 2024
garg vipin k
acquired
-
-
18,950
president and ceo
Feb 02, 2024
garg vipin k
sold (taxes)
-78,064
9.32
-8,376
president and ceo
Feb 02, 2024
roberts m scot
sold (taxes)
-21,715
9.32
-2,330
chief scientific officer
Feb 02, 2024
harris matthew scott
sold (taxes)
-21,734
9.32
-2,332
chief medical officer
Feb 02, 2024
harris matthew scott
acquired
-
-
7,775
chief medical officer
Feb 01, 2024
garg vipin k
acquired
-
-
16,545
president and ceo
Feb 01, 2024
roberts m scot
sold (taxes)
-17,793
9.88
-1,801
chief scientific officer
Feb 01, 2024
roberts m scot
acquired
-
-
6,166
chief scientific officer
Feb 01, 2024
garg vipin k
sold (taxes)
-72,252
9.88
-7,313
president and ceo

1–10 of 50

Which funds bought or sold ALT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
33.54
124,000
151,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-53.02
1,197,000
2,356,000
0.20%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
865
1,125
-%
Feb 15, 2024
Main Street Group, LTD
new
-
5,028
5,028
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
884
6,376,730
6,530,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
214
214
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-59.86
344,000
814,000
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-7.14
37,054
49,331
-%
Feb 14, 2024
SILVERCREST ASSET MANAGEMENT GROUP LLC
unchanged
-
895,275
1,164,380
0.01%
Feb 14, 2024
Laurion Capital Management LP
sold off
-100
-2,105,180
-
-%

1–10 of 45

Are Funds Buying or Selling ALT?

Are funds buying ALT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALT
No. of Funds

Unveiling Altimmune Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
ameriprise financial inc
7.79%
4,183,682
SC 13G
Feb 14, 2024
nuveen asset management, llc
0.01%
6,679
SC 13G/A
Feb 14, 2024
teachers advisors, llc
0.01%
6,679
SC 13G/A
Feb 14, 2024
tiaa cref investment management llc
0.01%
6,679
SC 13G/A
Feb 14, 2024
avidity partners management lp
0.0%
0
SC 13G/A
Feb 14, 2024
tang capital partners lp
5.1%
2,750,000
SC 13G/A
Feb 13, 2024
vanguard group inc
6.65%
3,571,972
SC 13G/A
Feb 12, 2024
janus henderson group plc
0.0%
273
SC 13G/A
Jan 26, 2024
blackrock inc.
7.5%
4,044,707
SC 13G
Jan 23, 2024
state street corp
1.89%
1,014,546
SC 13G/A

Recent SEC filings of Altimmune Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading

Peers (Alternatives to Altimmune Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Altimmune Inc News

Latest updates
InvestorsObserver19 hours ago
Yahoo Finance20 Feb 202403:26 pm
InvestorsObserver20 Feb 202412:21 pm
InvestorPlace2 months ago

Altimmune Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue5933.3%362,0006,00021,00011,5002,0008,0001,642,5003,277,000158,000137,000838,0002,312,7062,937,991721,6362,212,694575,802643,9781,626,0292,955,5922,588,6552,634,393
Operating Expenses27.1%22,902,00018,013,00021,780,00022,984,00024,754,00020,403,00019,531,00027,262,00033,362,00025,001,00015,699,00013,062,50121,262,21319,139,6069,519,4484,887,91211,917,3585,176,9135,284,15329,934,6356,692,459
  S&GA Expenses-5.2%4,514,0004,760,0004,531,0003,805,0004,492,0004,410,0004,427,0003,777,0004,156,0003,659,0003,821,0004,111,9294,220,2382,545,3562,331,9172,014,8232,187,6612,231,8172,066,4822,419,9511,963,733
  R&D Expenses38.7%18,388,00013,253,00017,249,00019,179,00020,262,00015,993,00015,104,00020,185,00029,206,00013,272,00011,878,0008,950,57217,041,97516,594,2507,187,5312,873,0898,729,6972,945,0963,217,6713,064,6734,728,726
EBITDA Margin-0.5%-19.66-19.56-19.42-19.30-21.95-21.86-21.87-21.89-24.15-10.96-9.07-6.60---------
Interest Expenses1350.0%29,0002,0002,000-183,00064,00065,00062,000-62,00033,00022,00012,0001,9532,2753,3081,885-756748740127,353166,946
Income Taxes----3,000-200,000-------110,346-482,017-1,578,782-3,245,879--58,500---2,831,670-829,393
Earnings Before Taxes-Infinity%-20,671,000---21,660,000-23,713,000---23,889,092-33,510,000-24,826,707-14,864,108-10,732,123-18,252,152-18,345,698-7,131,528-4,096,625-10,997,812-3,386,888-2,097,306-27,339,293-3,180,542
EBT Margin0%-19.25-19.25-19.25-19.25-22.02-22.02-22.02-22.02-24.36-11.03-9.13-6.65---------
Net Income-28.7%-20,671,000-16,061,000-20,074,000-21,660,000-23,516,000-20,107,000-19,430,000-23,889,000-33,510,000-24,827,000-14,864,000-10,621,777-17,770,135-16,766,916-3,885,649-4,096,625-10,939,312-3,386,888-2,097,306-24,507,623-2,351,149
Net Income Margin3.5%-17.79-18.44-19.36-19.21-19.71-21.98-23.05-22.02-24.33-10.94-8.81-5.99---------
Free Cashflow-5.7%-20,487,000-19,379,000-19,458,000-17,344,000-15,110,000-16,723,000-13,535,000-22,114,000-17,845,000-26,618,000-23,778,000-13,386,188---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-9.1%16718318720722521020621923725726424523310354.0054.0056.0062.0065.0055.0053.00
  Current Assets-9.8%15317017319321119619120421823924523021888.0040.0039.0042.0046.0049.0039.0012.00
    Cash Equivalents-15.1%87.0010210511112713618019017517415011614465.0011.009.0011.0042.0045.0034.008.00
  Net PPE-13.3%1.001.001.001.001.001.001.001.005.005.005.001.001.001.001.001.001.001.001.001.001.00
Liabilities3.7%16.0016.0019.0022.0020.0015.0021.0020.0028.0016.0018.0019.0033.0023.0012.009.007.006.006.006.0013.00
  Current Liabilities3.8%12.0011.0015.0017.0016.0014.0019.0018.0019.009.0010.0012.006.005.006.004.002.003.004.005.008.00
Shareholder's Equity-10.3%15016816818520519518519920924124622620080.0042.0046.0049.0056.0059.0048.0040.00
  Retained Earnings-5.0%-434-414-397-377-356-332-312-293-269-235-210-186-175-158-141-137-133-122-118-116-92.35
  Additional Paid-In Capital0.6%590587571568567532503497484482462417381243188188188184183170137
Shares Outstanding0.4%53.0053.0049.0049.0049.0048.0044.0041.0041.0041.0039.0037.00---------
Float------538---387---281---29.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-5.7%-20,487-19,383-19,407-17,306-15,050-16,704-13,526-21,967-17,775-18,927-19,569-13,282-9,504-7,170-4,347-2,002-2,426-3,060-2,112-5,155-1,022
  Share Based Compensation-2.7%2,7102,7862,6751,8922,1282,0482,0331,3191,4971,4851,2187101,32033121527928829040869.0096.00
Cashflow From Investing10.4%4,4023,98713,302981-25,403-48,968-9.0024,86918,41125,07819,165-36,999-47,8886,0986,563-52.68-28,216-12.85-4.25-8.13-153
Cashflow From Financing-95.5%58813,065-302-43.0032,06021,5833,18112,53512518,01934,41922,704136,14654,53997.0045.00-55.79-15612,69931,5184,413

ALT Income Statement

2023-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS    
Revenues$ 362$ 2$ 389$ 42
Operating expenses:    
Research and development18,38820,26248,89051,359
General and administrative4,5144,49213,80513,329
Total operating expenses22,90224,75462,69564,688
Loss from operations(22,540)(24,752)(62,306)(64,646)
Other income (expense):    
Interest expense(29)(64)(33)(191)
Interest income1,8841,0535,3871,402
Other income (expense), net1450146185
Total other income (expense), net1,8691,0395,5001,396
Net loss before income taxes(20,671)(23,713)(56,806)(63,250)
Income tax expense (benefit) (197) (197)
Net loss(20,671)(23,516)(56,806)(63,053)
Other comprehensive income - unrealized gain (loss) on short-term investments56(143)103(263)
Comprehensive loss$ (20,615)$ (23,659)$ (56,703)$ (63,316)
Net loss per share, basic$ (0.39)$ (0.48)$ (1.10)$ (1.37)
Net loss per share, diluted$ (0.39)$ (0.48)$ (1.10)$ (1.37)
Weighted-average common shares outstanding, basic53,633,35449,286,53551,495,95745,881,547
Weighted-average common shares outstanding, diluted53,633,35449,286,53551,495,95745,881,547

ALT Balance Sheet

2023-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 86,855$ 111,097
Restricted cash4134
Total cash, cash equivalents and restricted cash86,896111,131
Short-term investments53,92473,783
Accounts receivable876173
Income tax and R&D incentive receivables3,6532,368
Prepaid expenses and other current assets7,6155,358
Total current assets152,964192,813
Property and equipment, net7651,081
Indefinite-lived intangible asset12,41912,419
Other assets425615
Total assets166,573206,928
Current liabilities:  
Accounts payable3,0464,804
Accrued expenses and other current liabilities8,82512,250
Total current liabilities11,87117,054
Other long-term liabilities4,3054,581
Total liabilities16,17621,635
Commitments and contingencies (Note 10)
Stockholders' equity:  
Common stock, $0.0001 par value; 200,000,000 shares authorized; 52,858,920 and 49,199,845 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively55
Additional paid-in capital590,206568,399
Accumulated deficit(434,690)(377,884)
Accumulated other comprehensive loss, net(5,124)(5,227)
Total stockholders' equity150,397185,293
Total liabilities and stockholders' equity$ 166,573$ 206,928
ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEaltimmune.com
 EMPLOYEES52

Altimmune Inc Frequently Asked Questions


What is the ticker symbol for Altimmune Inc? What does ALT stand for in stocks?

ALT is the stock ticker symbol of Altimmune Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Altimmune Inc (ALT)?

As of Thu Feb 22 2024, market cap of Altimmune Inc is 476.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALT stock?

You can check ALT's fair value in chart for subscribers.

What is the fair value of ALT stock?

You can check ALT's fair value in chart for subscribers. The fair value of Altimmune Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Altimmune Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Altimmune Inc a good stock to buy?

The fair value guage provides a quick view whether ALT is over valued or under valued. Whether Altimmune Inc is cheap or expensive depends on the assumptions which impact Altimmune Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALT.

What is Altimmune Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ALT's PE ratio (Price to Earnings) is -6.07 and Price to Sales (PS) ratio is 106.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Altimmune Inc's stock?

In the past 10 years, Altimmune Inc has provided -0.187 (multiply by 100 for percentage) rate of return.